Document Detail


Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?
MedLine Citation:
PMID:  16193198     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The authors investigated the effects of rosuvastatin, beyond its lipid-lowering activity, on several nonlipid metabolic variables, along with its safety and tolerability, in patients treated for primary hyperlipidemia. Patients (n = 55) with primary hyperlipidemia were open-label assigned to the recommended starting dose of rosuvastatin 10 mg/day, and serum metabolic variables were measured at baseline and after 8 and 20 weeks. Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. The LDL-C treatment target was achieved in 71% of patients. No significant variations in renal function parameters (serum creatinine and creatinine clearance), insulin resistance estimates, and serum concentrations of uric acid, total homocysteine, vitamin B12, and folic acid were observed during the period of treatment. High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p < 0.0001). In conclusion, rosuvastatin at 10 mg/day is a highly effective, safe, and well-tolerated monotherapy option for patients with primary hyperlipidemia, with a favorable antiinflammatory potential and nondeteriorating effects on renal function.
Authors:
Haralampos J Milionis; Irene F Gazi; Theodosios D Filippatos; Vasilios Tzovaras; George Chasiotis; John Goudevenos; Konstantine Seferiadis; Moses S Elisaf
Related Documents :
11427208 - The combined effect of inhibiting both acat and hmg-coa reductase may directly induce a...
14744838 - Conceptual foundations of the ucsd statin study: a randomized controlled trial assessin...
17191138 - Alzheimer's disease and cholesterol: the fat connection.
20141348 - A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin...
11426438 - The effects of restricted energy and fluid intake on simulated amateur boxing performance.
6576198 - Influence of dietary fat on spontaneous lesions of syrian golden hamsters.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Angiology     Volume:  56     ISSN:  0003-3197     ISO Abbreviation:  Angiology     Publication Date:    2005 Sep-Oct
Date Detail:
Created Date:  2005-09-29     Completed Date:  2005-11-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  585-92     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
C-Reactive Protein / analysis
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Female
Fluorobenzenes / administration & dosage,  adverse effects,  therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Hyperlipidemias / drug therapy*
Kidney / drug effects
Male
Middle Aged
Pyrimidines / administration & dosage,  adverse effects,  therapeutic use*
Sulfonamides / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Walnut consumption in hyperlipidemic patients.
Next Document:  Do different atrial flutter types carry the same thromboembolic risk?